Clinical trial
RItuximab Versus FUmarate in Newly Diagnosed Multiple Sclerosis.
NCT02746744
Study timeline
Study start (actual)2016-05-01Date precision: month
Registry last updated2021-10-12
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Multiple Sclerosis, Relapsing-Remittingunresolved
Interventions
RituximabDRUG · verified · RxNorm: rituximab
Dimethyl fumarateDRUG · verified · RxNorm: dimethyl fumarate
Sponsors & collaborators
Anders Svenningssonlead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT02746744 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.